Nxera Pharma Co. Ltd. (SOLTF)
Market Closed
7 Aug, 20:00
$
5. 01
0
0%
$
670.92M Market Cap
- P/E Ratio
10% Div Yield
1 Volume
- Eps
$ 5.01
Previous Close Want to track SOLTF and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
SOLTF closed Friday higher at $5.01, an increase of 0% from Thursday's close, completing a monthly decrease of -21.3501% or -$1.36. Over the past 12 months, SOLTF stock lost -10.5357%.
SOLTF pays dividends to its shareholders, with the most recent payment made on Jun 24, 2015. The next estimated payment will be in 24 Jun 2015 on Jun 24, 2015 for a total of $10.
The last earnings report, released on May 01, 2026, exceeded the consensus estimates by 0%. On average, the company has fell short of earnings expectations by -24.6333%, based on the last three reports.
Nxera Pharma Co. Ltd. has completed 2 stock splits, with the recent split occurring on Jun 28, 2018.
The company's stock is traded on 7 different exchanges and in various currencies, with the primary listing on JPX (JPY).
Nxera Pharma Co. Ltd. (SOLTF) FAQ
What is the stock price today?
The current price is $5.01.
On which exchange is it traded?
Nxera Pharma Co. Ltd. is listed on OTC PINK.
What is its stock symbol?
The ticker symbol is SOLTF.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 10%.
What is its market cap?
As of today, the market cap is 670.92M.
Has Nxera Pharma Co. Ltd. ever had a stock split?
Nxera Pharma Co. Ltd. had 2 splits and the recent split was on Jun 28, 2018.
Nxera Pharma Co. Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Christopher Cargill CEO | OTC PINK Exchange | JP3431300007 ISIN |
| JP Country | 387 Employees | - Last Dividend | 27 Jun 2018 Last Split | - IPO Date |
Overview
Nxera Pharma Co., Ltd. operates as a biopharmaceutical company, with its sphere of operations spread across notable regions including Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Established in 1990 and headquartered in Tokyo, Japan, Nxera Pharma specializes in developing and marketing a diverse range of biopharmaceutical products. The company has forged strategic collaborations with industry giants such as AbbVie, Biohaven, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and Verily to enhance its research capabilities and expand its product portfolio.
Products and Services
- Ultibro/Breezhaler & Seebri/Breezhaler: Targeted for the treatment of chronic obstructive pulmonary disease (COPD), these products offer relief and improved breathing for individuals suffering from this condition.
- Enerzair & Breezhaler: Dedicated to asthma patients, these treatments aim to manage and control asthma symptoms, facilitating better respiratory health.
- ORAVI: A novel formulation designed to treat oropharyngeal candidiasis, ORAVI addresses fungal infections in the mouth and throat area, showcasing the company's commitment to tackling a range of infectious diseases.
- PIVLAZ: Developed for the treatment of cerebral vasospasm, PIVLAZ represents Nxera's foray into neurovascular care, aiming to alleviate conditions related to narrowed brain vessels.
- Development Pipeline: Nxera Pharma is actively involved in developing innovative therapies for a variety of health conditions, including:
- HTL0039732: Aimed at immuno-oncology indications, highlighting the company's contributions to cancer treatment.
- HTL0048149: Focused on addressing schizophrenia disorders, this product is part of Nxera's commitment to improving mental health treatments.
- Daridorexant: Developed for treating insomnia, demonstrating Nxera's attention to enhancing sleep quality for those affected.
- HTL0016878, PF-07081532, PF-07054894, PF-07258669, PF-06954522, NBI-1117569, and NBI-1117570: This range of products targets various conditions including schizophrenia, neuropsychiatric disorders, Type 2 diabetes mellitus and obesity, inflammatory bowel disease, anorexia, metabolic diseases, neurology diseases, and central nervous system (CNS) disorders, illustrating the breadth of Nxera's research and development efforts.
- Preclinical Stage Drugs: Nxera is also pioneering in the development of a GPR35 agonist for inflammatory bowel disease/GI disorders, along with other discovery and preclinical stage drugs, signaling the company's ongoing investment in future therapeutics.
Contact Information
Address: PMO Hanzomon
Phone: 81 3 5210 3290
Website: https://soseiheptares.com
